晚期非小细胞肺癌免疫治疗生物标志物及疗效预测的研究进展OA
Research progress on biomarkers and treatment response prediction for immunotherapy in advanced non-small cell lung cancer
晚期非小细胞肺癌(NSCLC)病人对于免疫治疗反应存在较大差异,通过生物标志物或直接预测疗效对于筛选受益人群具有重要意义.本文就AI模型在晚期NSCLC免疫治疗生物标志物预测、非传统生物标志物构建及免疫治疗疗效预测等方面的研究进展、面临的挑战和未来研究方向进行阐述和分析.
Patients with advanced non-small cell lung cancer(NSCLC)exhibit considerable variability in response to immunotherapy.The use of biomarkers or direct prediction of treatment efficacy is of great significance for identifying populations that may benefit.This review elaborates and analyzes the research progress,challenges,and future research directions of AI models in predicting immunotherapy biomarkers,developing non-traditional biomarkers,and predicting treatment response in advanced NSCLC.
胡嘉捷;石磊
浙江中医药大学第二临床医学院,杭州 310053浙江省肿瘤医院放射科,中国科学院杭州医学研究所
医药卫生
非小细胞肺癌免疫治疗生物标志物人工智能疗效预测影像组学
Non-small cell lung cancerImmunotherapyBiomarkerArtificial intelligenceTherapeutic effect predictionRadiomics
《国际医学放射学杂志》 2026 (2)
190-196,7
国家自然科学基金面上项目(82272085)
评论